E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients after transurethral R0-resection (TUR) of a histologically confirmed superficial bladder carcinoma (pTa low grade [multilocular or recurrence], pT1 low grade); re-resections included. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10046518 |
E.1.2 | Term | Urinary bladder carcinoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the maximum tolerated dose (MTD) of a mistletoe-extract (oak) manufactured by WELEDA (WEME 200 mg) in intravesical instillation in the selected patient population, based on the incidence of dose-limiting toxicities (DLTs), to describe the optimal dose ranges for putative phase II/III trials. |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate safety and tolerability of different dosages of intravesically applied mistletoe extract (WEME 200 mg).
2. To acquire first data about the clinical effects of intravesical instillation of WEME 200 mg in superficial bladder carcinoma. - To describe tumor recurrence rate 3, 6, 9 and 12 months after start of therapy. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age: 18 - 80 years. 2. Histologically confirmed superficial bladder carcinoma: pTa low grade [multilocular or recurrence] or pT1 low grade; re-resected tumours included. 3. No evidence of lymph node involvement and/or metastasis. 4. Transurethral R0-resection of the bladder tumour and immediate instillation of mitomycin C (dosage and administration according to respective SmPC) within 2 - 7 weeks before inclusion into the study; re-resection of the tumour included. 5. Patient information according to applicable national legislation and international guidelines followed by signing and dating the informed consent form. 6. Female, pre-menopausal patients must provide negative pregnancy test within two weeks before study entry and are willing to apply a highly effective birth-control method.
|
|
E.4 | Principal exclusion criteria |
1. Bladder carcinomas with one or more of the following characteristics: Carcinoma in situ (pTis), pT2-4, N1-3, M1, G3-4; furthermore are excluded pTa-tumours with low grade-grading which are not multilocular or recurrent. 2. Previous intravesical instillation therapy within the last 6 months (except previous immediate instillation of mitomycin C at day of transurethral R0-resection). 2.b Secondary damage of previous administration of intravesical chemotherapy, e.g. necrosis of urothelium or stenoses. 3. Previous radiation therapy. 4. Bladder resection. 5. Contracted bladder with capacity < 100 ml. 6. Inadequately treated acute or chronic urinary tracts infections. 7. Secondary neoplasia. 8. Co-morbidity with one of the following: active tuberculosis, active thyroid hyperfunction, known secondary cancer, HIV-infection/ AIDS, other severe systemic diseases as cardiac insufficiency, parasitosis or Crohn’s disease, acute inflammatory diseases with body temperature > 38 °C. 9. Other concomitant diseases likely to make participation of the patient difficult at the discretion of the investigator. 10. Clinically relevant cardiac arrhythmias. 11. Severe allergic illness (including asthma); known hypersensitivity to mistletoe products. 12. Any other current or planned oncological therapy (surgery, radiotherapy, chemotherapy, other mistletoe products including s.c. therapy with Iscador®). 13. Previous medical therapy that could interfere with the objectives of this study including mistletoe therapy within the last month. 14. Concomitant treatment with other immunomodulatory medications. 15. Known abuse of medicaments, alcohol or illegal drugs. 16.Laboratory parameters outside the following limits: Creatinine > 2x upper limit of normal Bilirubine > 3x upper limit of normal Transaminases > 3x upper limit of normal 17. Pregnancy or breast-feeding. 18. Pre-menopausal women not applying an effective birth control method. 19. Doubt concerning the compliance. 20. Previous participation in this clinical trial earlier in study course. Participation in any other clinical trial currently or within the last month. 21. Subjects which are in a state of dependence in relation to the sponsor’s or investigator’s institutions or which are their employees.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Estimation of the MTD (i.e., the highest dose applied provoking a dose-limiting toxicity [DLT] at a probability of maximally 33%) by fitting an a priori set dose-toxicity-relationship model to the observed rate of DLTs according to a modified version of the ‚Continual Reassessment Method (CRM)’. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Model based dose escalation is stopped either if >= 9 patients were treated on a given dose level and model predicts next patient to be treated at same level; or if actual dose level can be regarded as MTD with a probability of >= 90% (in both cases, actual dose level will be defined as MTD); or if maximum envisaged sample size of 24 patients has been included. In any case the last visit of the last patient (last patient: see aforementioned definition) will define the end of the clinical phase. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |